Condition: ALS (Amyotrophic Lateral Sclerosis) · Postpoliomyelitis Syndrome · Spinal Muscular Atrophy · Sponsor: University of Dublin, Trinity College
Motor neuron disease (MND) or ALS is a nervous system disease. ALS leads to a loss of movement ability that eventually leads to death. At the moment, there is no known treatment for ALS. Early diagnosis in individuals improves clinical care and facilitates timely entry into clinical trials. However, current methods for diagnosis are primarily clinical, and to date, no cost-effective biomarkers have been developed. Our objective is to identify a robust non-invasive neurophysiological-based system that can be used both as a biomarker of disease onset, and a measurement of progression using quantitative EEG and surface EMG (bipolar and high-density). The investigators postulate that analysing the joint recordings of EEG and EMG (bipolar or high-density) can give measures that better distinguish healthy people and ALS patient subgroups and that the findings can be developed as biomarkers of early diagnosis and disease progression.
This description comes directly from the study's public registry record.
Orla Hardiman, BSc MB BCh BAO MD FRCPI FAAN · +353 1 896 4497 · hardimao@tcd.ie
Saroj Bista, MSc · +353 89 945 8246 · sbista@tcd.ie
Always discuss trial participation with your own doctor first.
| Academic Unit of Neurology, Trinity College Dublin, The University of Dublin | Dublin, Leinster, Ireland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05663008